Miami-based proptech startup modernizes title search and property verification with AI and blockchain; seed round led by Cofounders Capital and FIT Ventures

MIAMI, Jan. 14, 2026 — Titl, a proptech company modernizing property title verification using AI and blockchain, today announced it has closed a $2.5 million seed funding round. The investment will accelerate Titl’s national expansion as demand grows for faster, more transparent, and more secure title search, monitoring, and storage (land registry) that reduces turnaround times from days to minutes. 

The seed round was led by Cofounders Capital and FIT Ventures. Titl will use the new funding to scale operations beyond Florida, with immediate expansion plans in Georgia, Maryland, and Connecticut. The company plans to expand to almost 20 states before the end of the year.

Why Titl, why now: real estate went digital, but title verification didn’t

Much of the homebuying experience has become digital and near-instant, yet title verification still often relies on manual work across fragmented county records, introducing delays and risk into transactions. It begs the question: why does it take more than a week to validate that a home is ready to be sold, and why is this validation typically performed only at the point of transaction, rather than at the time of listing?

Because property records are fragmented across thousands of local jurisdictions, title research is often slow, inconsistent, and hard to verify. Titl is building a digital, unified land registry that standardizes and connects these records, making ownership verification and transfer faster, more transparent, and more reliable. Leading companies are spending millions of dollars annually on property searches and verification, which inevitably impacts homeowners.  

At the same time, real estate-related cybercrime remains a costly and persistent threat: the FBI’s 2024 Internet Crime Report shows reported losses for “Real Estate” crime totaling $173,586,820 in 2024. This was made easier by the manual and paper-based nature of property records, deep fakes, artificial intelligence, title fraud and identity fraud that have become an ever-growing risk.

What Titl does

Titl automates title search and continuously monitors for changes that can impact ownership – bringing speed, auditability, and security to an industry that historically hasn’t had it, and laying the groundwork for a unified, digital source of truth across fragmented land records.

Titl uses AI to surface critical property information – ownership history, liens, taxes, code violations, permits, and related documents – and leverages an immutable blockchain ledger designed to make records tamper-resistant and independently verifiable.

“We set out to find an extremely niche, inefficient process where we could create a significant impact and the title process was it,” said Ori Ohayon, Co-founder of Titl. “Titl is unifying property ownership verification and transfer through a centralized, digitized U.S. registry. We’re not digitizing yesterday’s workflow; we’re reimagining ownership for the digital age.”

Founded by Goldman Sachs Veteran and a Real Estate Developer

Titl was created by Ori Ohayon, a serial entrepreneur and former Goldman Sachs banker and Tory Ricalis, a real estate developer with a deep passion in blockchain-enabled innovation. 

Ohayon worked on web3 enabled solutions at both at Goldman Sachs and TD Securities, bringing firsthand experience across traditional finance and emerging technologies and a track record for spotting inefficiencies in legacy systems.

Ricalis brings practical, on the ground experience from real estate development, having managed complex projects and navigated the pain points of property transactions. Through that work, he experienced the friction in real estate purchases firsthand and realized there had to be a better way. 

Product suite and early traction

Since launching in January 2022, Titl has built products that support title search, production, and ongoing risk detection across the title lifecycle. 

Core offerings include:

• TitlReport: Delivers comprehensive title reports in about four minutes, using AI to analyze liens, encumbrances, and ownership history with verified source records.
• TitlProduction: Automates title production by extracting key data from closing packages to generate title reports and commitments in moments, while flagging risks and reducing manual rework.
• TitlMonitoring: Always-on title surveillance with instant fraud alerts to help protect owners and lenders from unauthorized liens, forged documents, and ownership takeover attempts.
• TitlCheck: A pre-listing title check that gives sellers and agents a clear, high-level read on potential issues that could delay a closing so problems are identified early, not at the finish line.

“We are thrilled to invest in this technology and team. AI-powered applications like this create real demonstrable value for customers and investors,” said David Gardner, Founding Partner at Cofounders Capital. Gardner, who led six successful enterprise SaaS exits before founding Cofounders Capital, will join the company’s board. He and the Cofounders Capital team bring deep experience scaling B2B software companies like Titl.

“FIT Ventures is excited to join the founders of Titl on their journey to help modernize an antiquated industry as they build new, essential infrastructure for American land registries,” said Brian Becker, partner, F.I.T. Ventures.

About Titl

Titl is a real estate technology company modernizing the title industry through AI and blockchain innovation. By providing automated title search, real-time property monitoring, and fraud-resistant transaction tools, Titl helps lenders, brokers, and government agencies close deals faster, with greater accuracy and less risk. Our flagship products, TitlReport, TitlCheck, TitlProduction, and TitlMonitoring, simplify the title lifecycle from search to settlement. Headquartered in Downtown Miami, Titl is building a digital-first land registry. infrastructure that brings transparency, efficiency, and security to property ownership across the United States.

Media Contact:
Joshua Milne
617-501-1620
[email protected] 

SOURCE Titl

OpenAssets is establishing open standards for the next generation of capital markets—the trusted foundation for real-world asset tokenization infrastructure.

PITTSBURGH, Jan. 14, 2026 — OpenAssets today announced its launch as the new parent brand of Pointsville. OpenAssets builds on the proven experience and infrastructure from the team behind Pointsville’s tokenization and loyalty products, delivering secure digital value systems at scale designed for institutional and sovereign use. As global demand for real-word asset tokenization accelerates, OpenAssets aims to provide the foundation for enduring adoption.

As capital markets accelerate toward digital issuance and faster settlement, institutions face growing pressure to adopt new infrastructure without introducing operational risk or vendor lock-in. OpenAssets addresses this challenge with open standards-based architecture that enables asset tokenization using institutional-grade security, compliance readiness, and seamless integration into existing financial systems.

OpenAssets products and technologies were designed from the ground up for regulated environments and standards-based governance. Its open architecture prevents vendor lock-in, supports interoperability across jurisdictions, and ensures institutions and governments retain full authority over assets, policies, and data, which are foundational requirements for financial infrastructure intended to operate in the public interest at national and global scale.

OpenAssets is backed by a funding round led by Valor Capital Group with participation from global investors and industry leaders across finance, compliance, and digital infrastructure, including Tether, members of the founding family of Itaú Unibanco, Nubank’s co-founder, Temasek-backed Superscrypt, SNZ, Credit Saison, K2 Integrity, Citrino, and partners of Dynamo, reflecting broad confidence in the need for open, governance-first financial infrastructure for institutional and sovereign adoption.

In addition to housing the tokenization and loyalty products by Pointsville under its umbrella and growing its focus on digital financial infrastructure at the institutional level, OpenAssets will also move to address a market need for agentic commerce infrastructure in the near future.

For media inquiries, contact: [email protected] | www.openassets.to

About OpenAsssets

OpenAssets builds open infrastructure for digital financial systems. Founded in 2026, the company establishes the standards and foundational technology that enable institutions to modernize capital markets with infrastructure designed for interoperability, governance, and public trust. Learn more at openassets.to.

SOURCE Pointsville

Healthcare Firm to Invest in Company’s Expanding Platform of Pharmacy Solutions

CHICAGO, Jan. 14, 2026 — Strategic health care investor Water Street Healthcare Partners announced today that it has invested in Pillr Health, a premier provider of software and tech-enabled services that optimize pharmacy operations for health care delivery organizations. Water Street will invest its team’s industry knowledge and resources, along with its capital, to broaden Pillr Health’s platform of pharmacy solutions.

“Our partnership with Water Street is the next important step toward advancing our mission of empowering health care organizations with cutting-edge solutions, and ensuring operational excellence through integrity, exceptional service, and relentless innovation,” said Skip Devanny, CEO, Pillr Health. “With Water Street’s industry expertise, network, and capital, we will focus on accelerating development of new solutions that enable our clients to optimize clinical care while capturing meaningful economic value from their pharmacy operations.”

Pillr Health helps hospitals and health systems optimize and streamline their pharmacy operations, particularly within the 340B federal outpatient drug pricing program, which provides significant cost savings to providers serving vulnerable patient populations. The company’s integrated platform of software, analytics, and advisory services streamlines workflows, improves regulatory oversight, and strengthens the performance of pharmacy programs. Serving more than 300 hospitals and health systems across the U.S., Pillr Health recently launched a new product empowering clients to start their own outpatient retail and specialty pharmacy services.

“Pillr Health has established itself as an essential partner to hospitals and health systems seeking to maximize their pharmacy performance in an increasingly complex landscape,” said Max Mishkin, partner, Water Street. “We look forward to working with leadership to broaden Pillr’s differentiated technology platform and extend its national reach through a combination of organic investments and strategic acquisitions offering complementary capabilities and market growth opportunities.”

Patrick Teyro, principal, Water Street, added: “Pillr’s pharmacy expertise and innovative solutions are vital for helping providers expand their health services under constrained budgets to deliver high-quality clinical care. We are honored to work with Skip and his team to advance their goal of becoming a leader in hospital pharmacy enablement.”

Mr. Devanny and the management team will continue to lead Pillr Health. Cantor Fitzgerald served as an advisor to Water Street in the transaction. Financial details are not disclosed.

ABOUT PILLR HEALTH

Pillr Health is dedicated to transforming health care through cutting-edge solutions that enhance efficiency, optimize resources, and improve patient outcomes. The company specializes in 340B program administration, helping hospitals and health systems maximize performance in the federal outpatient drug pricing program, which provides discounts to organizations serving uninsured, low-income, and vulnerable patient populations. Headquartered in Boca Raton, Florida, Pillr Health serves more than 300 health care organizations nationwide through its comprehensive platform of software, analytics, and managed pharmacy offerings.

ABOUT WATER STREET

Water Street Healthcare Partners is a strategic investor dedicated to building market-leading businesses in three critical health care sectors: medical products and diagnostics, pharmaceutical and life sciences, and health care services. The firm has completed more than 165 investments and acquisitions to build 48+ companies contributing to improved patient care, innovation, and a more efficient health care system. Working closely with leadership teams, Water Street contributes its industry experience and network of resources to support businesses’ growth objectives. Based in Chicago, Water Street’s team is a distinctive blend of health care executives, investment professionals, and functional specialists with decades of experience investing in and operating global health care businesses. For more information, visit waterstreet.com.

CONTACT

Kelly Zitlow
[email protected] 

Subscribe to News

Visit Website

LinkedIn

SOURCE Water Street Healthcare Partners

New Funding Expands Access to Geospatial Imagery, Fueling Business Cases Across Diverse Sectors like Defense, Finance, and Agriculture with Actionable Data Analytics 

AUSTIN, Texas, Jan. 14, 2026 — SkyFi, an AI-first Earth intelligence platform, today announced that it has raised a $12.7 million in an oversubscribed Series A funding round. The round was co-led by Buoyant Ventures and IronGate Capital Advisors, with new participation from DNV Ventures, TFX Ventures, Beyond Earth Tech, Nova Threshold, and Chris Morisoli, and existing investors RSquared VC and J2 Ventures. This investment will accelerate product development and enhance SkyFi’s technology, including its platform’s user interface and analytical tools. Additionally, the company plans to forge new partnerships with satellite operators to expand its on-demand data offerings and AI-enabled analytic capabilities for leading commercial and government customers worldwide.

Co-founded by Luke Fischer and Bill Perkins, SkyFi’s growing network of more than 50 geospatial imagery partners currently provides optical, synthetic aperture radar (SAR), hyperspectral, and aerial imagery, as well as data analytics, to industries including defense, energy, finance, infrastructure and construction, environmental services, agriculture, insurance, and mining. The company’s intuitive, user-friendly web platform and mobile app are transforming how businesses, governments, and individuals acquire and analyze complex satellite imagery, providing actionable insights that enable customers to make informed decisions without the need for specialized expertise.

“This funding is a testament to the strong demand for a more accessible approach to Earth observation data,” said Luke Fischer, CEO and cofounder of SkyFi. “Geospatial intelligence is essential not only for military and defense purposes but for commercial uses as well. From asset and supply chain monitoring, to insurance and real estate, to energy utilities, agriculture, and environmental protection, we believe that powerful insights from space should be available to everyone, not just a select few. This capital will allow us to scale our platform and empower more customers globally to leverage satellite data to solve critical challenges across various industries.”

According to a report from the World Economic Forum in collaboration with Deloitte, the potential value-added from Earth data was estimated at $266 billion in 2023, a figure that is poised to grow to more than $700 billion in 2030. Cumulatively, the report suggests that Earth observation has the potential to drive $3.8 trillion in economic benefit from 2023-2030 while positively impacting climate and nature.

“SkyFi is transforming how we access and use geospatial data by making satellite insights affordable, intuitive, and widely available,” said Laura Katzman, partner at Buoyant Ventures. “Their platform opens the door to critical applications in energy, agriculture, climate monitoring, disaster response, and defense. We’re thrilled to back a team that is democratizing access to Earth Observation data and driving solutions to global challenges, especially at a time when federal and public data resources are dwindling.”

“The state of the world today requires rapid access to intelligence–not only for governments and their national security but for commercial entities and their operational success. SkyFi provides users with an intuitive, robust platform to derive on-demand insights from geospatial data and analytics,” said Hamlet Yousef, managing partner at IronGate Capital Advisors. “From supply chain disruptions to natural disasters, geopolitical tensions to environmental monitoring, the world’s toughest challenges necessitate accessible, actionable data in order to be solved. We are proud to back SkyFi, a true dual-use company that is making earth intelligence–and the answers it provides–available to all who need it.” 

SkyFi experienced significant growth in 2025, launching custom built platforms for leading commercial satellite partners, Vantor–formerly known as Maxar Intelligence, ICEYE US, and Planet to deliver on-demand access to the most advanced high-resolution imagery and analytics.

The company was also selected via a rigorous evaluation process to participate in the North Atlantic Treaty Organization’s (NATO) Defence Innovation Accelerator for the North Atlantic (DIANA) 2026 Challenge Programme as one of 150 companies from 3,600 applications across 24 NATO countries.

About SkyFi

SkyFi is a self-service Earth Intelligence Platform that allows users to run built-in geospatial analytics, task satellites, and access archived imagery. The dual-use platform supports both civilian and defense use cases, with flexible ordering options, transparent pricing, and API access for large-scale workflows.

Customers can use SkyFi’s web platform, mobile app, or developer APIs to manage Earth observation projects without needing contracts or in-house GIS teams. Learn more at www.skyfi.com

SOURCE SkyFi

MANNHEIM, Germany, Jan. 14, 2026 — osapiens, a leading provider of enterprise software for sustainable growth, today announced that it had entered into an agreement for Decarbonization Partners, a joint venture between BlackRock and Temasek, to lead a US$ 100 million Series C fundraising round, subject to regulatory approvals. Decarbonization Partners will join existing investors Goldman Sachs Alternatives, which led the US$ 120 million Series B in 2024, and Armira Growth, which led the US$ 27 million Series A investment in 2023.

osapiens provides enterprise software that enables companies to manage regulatory compliance, sustainability, and operational efficiency across their entire value chain on a single platform. The osapiens HUB currently offers more than 25 enterprise-grade solutions, all of which run on a multi-tenant infrastructure that enables AI-driven automation and seamless cross-company collaboration. The platform combines transparency and efficiency solutions to help companies minimize risks, maximize efficiency, and respond with high agility and adaptability to changing regulatory and business requirements – setting industry standards.

The proceeds from the investment will be used to accelerate product innovation and fuel growth in existing and new international markets, further strengthening osapiens’ position as a global platform for sustainable growth.

“This investment is a strong validation of our strategy and our long-term vision,” said Alberto Zamora, Co-CEO and Co-Founder of osapiens. “It demonstrates that sustainable growth and AI-driven efficiency remain top priorities for global investors. Decarbonization Partners is an exceptional partner for us. With a focus on sustainability and the combined global presence and investment expertise of BlackRock and Temasek, they bring exactly the perspective and scale we need for our next phase of growth to become the indisputable global category leader in sustainable growth for enterprises of all sizes.”

Matthias Jungblut, Co-CEO and Co-Founder of osapiens, said: “Decarbonization Partners understands both the regulatory dynamics companies face today and the business opportunity of AI-driven efficiency that comes with it. Their deep experience in scaling category-defining technology companies makes them a perfect strategic fit alongside Goldman Sachs Alternatives and Armira Growth.”

“osapiens is redefining how companies achieve transparency, compliance, and operational excellence across increasingly complex supply chains,” said Dr. Meghan Sharp, Global Head and Chief Investment Officer of Decarbonization Partners. “Enterprises around the world are looking for trusted, scalable software to meet rising regulatory, sustainability and decarbonization expectations. osapiens’ platform delivers the clarity organizations need to operate and grow responsibly.”

About osapiens:

osapiens – one platform for sustainable growth

osapiens develops software that empowers companies to drive sustainable growth across their entire value chain. The osapiens HUB, a multi-tenant hyperscaler platform designed to enable cross-company collaboration and AI automation, combines over 25 solutions in two categories: Transparency solutions enable companies to report on financial and non-financial data, manage supply chains, mitigate risks of all kinds (including cyber-risks and trade- and geopolitical risks), and ensure compliance with product, reporting and supply chain regulations. Efficiency solutions enable AI-driven supplier collaboration, maintenance, service, and distribution processes to improve operational performance and strengthen competitiveness.

osapiens was founded in Mannheim, Germany in 2018 by Alberto Zamora, Stefan Wawrzinek, and Matthias Jungblut. Its international team of over 550 dedicated professionals across Europe and the United States supports more than 2,400 customers worldwide, including global category leaders like Coca-Cola North America, Lidl, Carrefour, OTTO, and the Acciona-Nordex Group.

About Decarbonization Partners:

Decarbonization Partners is a joint venture between Temasek and BlackRock focused on late-stage venture capital and early growth private equity investing in next-generation companies that provide solutions and technologies to help accelerate global efforts to achieve a net zero global economy by 2050. Decarbonization Partners combines Temasek and BlackRock’s complementary platforms and expertise in sourcing and underwriting private investments, portfolio and risk management, and sustainable technology and analytics. Decarbonization Partners invests in a wide range of companies that have proven technology and need capital to scale. The partnership attracted US$1.40 billion in capital from a diverse set of over 30 institutional investors across North America, Europe and Asia Pacific.

Photo: https://mma.prnewswire.com/media/2860577/osapiens_Founders.jpg
Logo: https://mma.prnewswire.com/media/2860576/osapiens_Logo.jpg

SOURCE Resonance

SARASOTA, Fla., Jan. 13, 2026 — Confianza, a comprehensive data and predictive analytics company, today announced the successful completion of its Series Seed 2 round of funding.

The funding will support the continued execution of Confianza’s growth strategy, focusing investment on the expansion of client-facing resources, and advanced AI/ML analytics and predictive modeling capabilities to accelerate its growth within the insurance ecosystem. These investments will further strengthen Confianza’s position in the insurance market while enabling expansion into additional industries and use cases with the proven value of its comprehensive data and analytics assets.

Confianza provides unique data and analytics solutions that improve the speed, accuracy, and efficiency of critical business processes. To date, the company has primarily served insurance carriers, MGA’s and wholesale brokers across personal and commercial lines, helping clients drive improved outcomes, operational efficiency and increased profitable growth, across the entire policy lifecycle. With one of the largest linked databases of people and businesses, Confianza is uniquely positioned to build, train, and power models of all kinds, including AI-driven and predictive analytics models, while seamlessly embedding data into customer workflows. The company’s deep expertise in AI/ML predictive modeling further differentiates its solutions within the data and analytics ecosystem.

“This funding reflects confidence in our strategy, our data assets, and the value we deliver to customers,” said Greg Johnson, CEO of Confianza. “It allows us to continue investing responsibly while expanding the impact of our solutions.”

Founded in 2020, Confianza serves organizations seeking data-driven solutions to improve risk selection, segmentation and profitable growth.

SOURCE Confianza, Inc.

PALO ALTO, Calif., Jan. 13, 2026 — RISA Labs, a company pioneering an AI operating system for oncology, today announced the closing of an $11.1 million Series A funding round. The financing was co-led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures, Z21 Ventures, and John Simon (co-founder of General Catalyst) via his Ventureforgood investment entity.

The funding will accelerate the deployment of RISA’s system to cancer clinics, health systems, specialty pharmacies, and infusion networks across the United States, changing how complex oncology workflows are managed end-to-end.

In oncology, delays are costly for all stakeholders: patients, practices, payers, and pharma. Addressing this, RISA orchestrates patient access, benefits verification, and prior authorization, turning manual bottlenecks into predictable, high-throughput workflows across the cancer service line. In just nine months, partner institutions have already expanded from initial deployment to second and third workflows, reflecting rapid adoption and operational trust.

“In our vision for oncology, there are two sides to every patient’s journey: getting them on the right therapy faster and deepening our understanding of the disease for the next patient through data,” said Kshitij Jaggi, CEO of RISA Labs.

RISA connects directly to a cancer center’s electronic medical record (EMR), payer and benefits systems, and other systems of record. A team of AI agents reads, reasons, and acts across these systems, gathering the right data, preparing and submitting authorizations, tracking status, and progressing cases across dozens of payer environments, EMRs and other tools. As forms, rules, or interfaces change, the agents adapt in real time, so workflows stay reliable without constant reprogramming. The AI OS is purpose-built for the realities of cancer care, handling complex payer rules, multi-drug regimens, and disease-specific requirements.

Teams manage and configure all of this through BOSS Console, RISA’s command control panel for mission-critical institutions. With BOSS Console, each institution can tailor workflows, routing, document conventions, and practice-specific rules so the system behaves like an extension of its own operations. Every AI action is traceable and audit-ready, giving leaders clear visibility into what the system did and why, and how it stays aligned with compliance and clinical standards.

RISA is already live at some of the largest oncology practices in the U.S. At one partner site, approximately 80% of administrative staff time has been freed up, denials have been reduced by up to 40%, and first-pass approval rates have reached 97.8%. Patient authorizations are now filed within 24 hours of request and are on track to drop below 2 hours, down from an average 8-day backlog. More than 20 full-time equivalents have been repurposed to higher-value work, increasing both capacity and efficiency across the practice.

“BOSS Console is a low-entropy thinking information machine,” said Kumar Shivang, CTO of RISA Labs. “Modern oncology has created thousands of potential care paths for every patient. It has become essential to have an intelligent operating system that can absorb this complexity, remove administrative burden, and act as a companion to the most informed clinical decisions.”

By leveraging AI to confront the looming challenge of a growing patient population, increasingly complex treatment strategies, and a limited supply of oncologists, RISA aims to address the core mathematical problem in modern cancer care.

“As the treatments available for oncology patients increase in number and complexity, solutions to help streamline operational processes and enable efficient access to therapy become vital.  We look forward to supporting RISA on their next phase of growth,” said Jason Dinger, Senior Vice President, Strategic Execution at Cencora.

In the coming year, RISA will go deeper in oncology, partnering with ecosystem leaders to expand AI-driven workflows across the full continuum of cancer care. Extending these capabilities to specialty pharmacy operations is the next step, built on the same foundation and configured through BOSS Console.

About RISA Labs

Founded by Kshitij Jaggi and Kumar Shivang, RISA Labs is the creator of BOSS Console that helps build AI OS for mission-critical institutions. Its first area of focus is oncology, where the system unifies access, benefits, and prior authorization across cancer centers, specialty pharmacies, and infusion networks so every eligible patient can start the right therapy faster.

Already deployed at leading oncology networks and community practices, RISA helps them operate with greater efficiency, capacity, and precision while strengthening financial performance: making institutions win in the age of AI. For more information, please visit Risa Labs at https://www.risalabs.ai

About Cencora Ventures

Cencora Ventures is the dedicated corporate venture capital fund of Cencora. Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 51,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $300 billion in annual revenue.      

CONTACT: Media Contact: [email protected] 

SOURCE RISA Labs

BOSTON, Jan. 13, 2026 — Diffraqtion, an MIT and University of Maryland spinout developing satellite constellations powered by a novel quantum camera, today announced the close of their pre-seed funding round, led by QDNL Participations, with participation from milemark•capital, Aether VC, ADIN, Offline Ventures, and a non-dilutive DARPA SBIR Direct-to-Phase 2 contract supporting space situational awareness capabilities. The total amount of funding between dilutive and non-dilutive raised is $4.2 million.

Founded by Johannes Galatsanos, Christine Wang, Ph.D., and Prof. Saikat Guha, Diffraqtion has developed a first-of-its-kind quantum camera that enables satellites and telescopes to see farther and process visual information dramatically faster than conventional systems. Built on Prof. Guha’s research with NASA and DARPA, the technology delivers up to 20 times higher resolution and 1,000 times faster processing than conventional cameras and processors, enabling ultra-high-resolution imaging systems at a fraction of the cost of today’s satellites and ground-based telescopes.

Diffraqtion’s novel approach enables the company to deploy large constellations of low-cost, high-precision satellites for space domain awareness, defense, and commercial Earth observation. These satellites support applications ranging from orbital safety and intelligence to agriculture, disaster response, and environmental monitoring.

In recent months, and in addition to the amount raised, the company has received multiple major recognitions, including:

• First place at SLUSH 100, selected from over 1,000 startups, resulting in an $1.1M equity prize from Cherry Ventures and General Catalyst
• TechConnect’s “2025 Best Space Innovation” $100k award

Diffraqtion is also part of the U.S. Space Force’s Apollo Accelerator, where it is actively demonstrating and refining its quantum imaging technology with government partners. In early 2026, the company plans to conduct on-sky demonstrations with the University of California Observatories, followed by space-based demonstrations.

“Space-based infrastructure powers our communications, navigation, and defense, and through Earth Imaging, it supports everything from agriculture to disaster response,” said Johannes Galatsanos, CEO and Co-Founder of Diffraqtion. “Yet despite the boom in low-cost launches, we still lack clear, continuous visibility of what’s happening above and below the atmosphere. Our quantum camera changes that: it tracks smaller, faster objects to keep assets in orbit safe, while delivering ultra-high-resolution imaging for critical applications on Earth.”

“Quantum sensing can bring new capabilities to monitoring and protecting orbital infrastructure,” said Chad Rigetti, Venture Partner at QDNL Participations “Diffraqtion’s team combines deep photonics and quantum expertise with practical defense and space insight – exactly what’s needed to bring quantum imaging into operational reality.”

About the Leadership

Johannes Galatsanos, Co-Founder and CEO, has over 15 years of experience in AI, Quantum Tech, and Operations. He’s an MIT and Oxford graduate, and has been an MIT researcher, Executive Director at Novartis, and Technical Consultant with a track record of building teams delivering Data and AI products across Manufacturing and R&D. 

Christine Wang, Co-Founder and CTO, did her Ph.D. at Harvard and Post-Docs at EPFL and Max Planck Institute. She has over 20 years experience in designing and prototyping photonics and optics devices for defense and commercial use, latest as Director of Optics and Photonics at Riverside Research and Principal Scientist at Draper Labs.

Prof. Saikat Guha, Co-Founder and CSA, is a world-renowned scholar in quantum sensing with over 100 papers and patents, over 10,000 citations, and inventor of Diffraqtion’s patented quantum imaging IP. He’s an IEEE Fellow, Distinguished Chair Prof. at the University of Maryland, adjunct faculty at MIT, and Director at the NSF Center for Quantum Networks.

Mark Michael, Head of Product, is the ex-CTO and Co-Founder of Kepler Communications, one of North America’s largest space companies. He is an Engineering graduate from University of Toronto and worked at IBM before Kepler.

About Diffraqtion

Diffraqtion is a Somerville, MA, space startup building the world’s first quantum camera powering the largest ultra-high-resolution imaging satellite network. Combining quantum photonics and AI, Diffraqtion enables machines to see further and think faster, advancing space exploration, defense, and intelligent systems worldwide.

About QDNL Participations

QDNL Participations is a $70 million specialized investment fund dedicated to investing in early-stage quantum technology companies worldwide. Established in 2022 by General Partner Ton van ‘t Noordende, the fund’s investment team operates across the Netherlands, the UK, and the US. 

Media Contact:
[email protected] 
www.diffraqtion.com

SOURCE Diffraqtion

• Financing led by Genesys Capital with participation from Cleveland Clinic and JobsOhio Ventures
• Genesys Capital Managing Partner Jamie Stiff to join Enspire Board of Directors
• Proceeds to support continued enrollment of the RESTORE pivotal clinical trial

CLEVELAND, Jan. 13, 2026 — Enspire DBS Therapy, Inc. (“Enspire”), a clinical-stage company developing an implantable neuromodulation therapy for post-stroke recovery, today announced that it has raised $10.3 million in a Series B1 financing led by new investor Genesys Capital, with participation from existing investors Cleveland Clinic and JobsOhio Ventures.

Proceeds from the financing will be used to continue enrollment in the multicenter RESTORE pivotal clinical trial, which evaluates deep brain stimulation combined with structured rehabilitation (“DBS + Rehab”) for patients with chronic upper-extremity impairment due to stroke. The RESTORE study is designed to generate the long-term safety and effectiveness data required to support future FDA marketing authorization. Interim results are expected in mid 2027.

“This financing represents an important milestone for Enspire as we advance RESTORE through pivotal clinical development,” said Scott Kokones, Chief Executive Officer of Enspire DBS Therapy. “With strong continued support from Cleveland Clinic and JobsOhio Ventures, and the addition of Genesys Capital as a new lead investor, we are well positioned to execute our clinical strategy and advance a potential first-in-class brain therapy for stroke recovery.”

As part of the financing, Jamie Stiff, Managing Partner at Genesys Capital, will join Enspire’s Board of Directors.

“Genesys Capital invests in companies developing transformative therapies across biotechnology, pharmaceuticals, and medical technology,” said Stiff. “The Enspire team has made remarkable progress advancing DBS-enabled rehabilitation for patients with neurological deficits following stroke. I am excited to join the Board and support the continued clinical progress of RESTORE and the company’s long-term vision.”

About Stroke
Approximately 800,000 people in the United States experience a stroke each year, making stroke a leading cause of long-term disability. While many patients survive the acute event, persistent neurological impairment often compromises quality of life and independence, with nearly 50% of survivors requiring assistance with daily activities.

About the RESTORE Pivotal Study
The RESTORE Stroke Pivotal Study is a multicenter clinical trial evaluating the safety and effectiveness of DBS + Rehab for improving arm strength and functional recovery following stroke. DBS for post-stroke rehabilitation is investigational and is being studied under Enspire’s FDA-approved Investigational Device Exemption (IDE).

Each participant is implanted with a commercially available third-party DBS system and completes a five-month outpatient rehabilitation program. Following a blinded, randomized five-month comparison between DBS + Rehab and rehabilitation-only control, participants initially assigned to control cross over to receive DBS and complete an additional five-month therapy phase. Results are expected in mid 2027.

For more information, visit ClinicalTrials.gov (NCT05701280) or www.restorestrokestudy.com. The RESTORE trial is actively recruiting.

About Enspire DBS Therapy
Enspire DBS Therapy, Inc., headquartered in Cleveland, Ohio, is a clinical-stage medical device company focused on developing neuromodulation therapies to restore function in patients living with disability after stroke. Founded in 2010, Enspire is a Cleveland Clinic portfolio company dedicated to translating breakthrough neuroscience into clinically meaningful outcomes.

For more information, visit www.enspiredbs.com.

About Genesys Capital
Genesys Capital is a Toronto-based venture capital firm investing in early-stage life sciences companies addressing areas of significant unmet medical need. With more than 25 years of experience, Genesys has generated over 20 exits and is widely recognized as Canada’s most successful life sciences venture firm. For more information, visit www.genesyscapital.com.

SOURCE Enspire DBS Therapy, Inc.